Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina

Detalhes bibliográficos
Autor(a) principal: MOURA, Julliana Rodrigues
Data de Publicação: 2009
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFG
dARK ID: ark:/38995/00130000002dn
Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tde/2087
Resumo: Olanzapine is an antipsychotic active ingredient and its marketing in Brazil, in the form of terminated product, is protected by patent up to 2011. As it is recent in the pharmaceutical market and there is not a methodology described in officials forms that is capable of assuring the quality of new formulations, the objective of this paper was to characterize Olanzapine physical-chemical parameters, to develop and validate, in accordance with RE N°899, from May 29 th 2003, the analytical methodology for assay and dissolution and to apply the developed and validated methodologies in the pharmacotechnical development of tablets. It was characterized some physicalchemical parameters of solubility and of light absorption (from 200 to 400nm) in several solvents and it was developed and validated assay and dissolution methodologies by spectrophotometry with ultraviolet detection (UV) and the assay by high efficiency liquid chromatography with ultraviolet detection (HPLC-UV) for the quantification of olanzapine present in film coated tablets of 2.5, 5.0 and 10.0mg. The active ingredient presented a low solubility in water and the wave lengths of maximum light absorption were within the range of 254 and 273nm. For the dissolution methodology by UV spectrophotometry, the parameters were chloride acid 0.1 mol/L as the dissolution media, volume of 1,000mL (5 and 10mg of Olanzapine) and 500mL (2.5mg of Olanzapine), apparatus II (paddles) and a rotation of 50 rpm. The spectrophotometric parameters were chloride acid 0.1 mol/L as blank and 259nm of wave length. For the assay methodology by UV spectrophotometry, it was used as a solvent and as a blank solution chloride acid 0.1 mol/L and a wave length of 259nm. It was used a ProStar 210 UV/VIS VARIAN high efficient liquid chromatographer, a C18 (150x4,6)mm 5μm column in room temperature (25ºC), a flux of 0,8mL/min, a wave length of 254nm and a mobile phase constituted of a mixture of monobasic potassium phosphate buffer 0,01 mol/L pH 2,5 and acetonitrile (70:30) for the assay methodology by HPLC-UV. The results found from the parameters of specificity, linearity, accuracy, precision, quantification and detection limits and stability in the methodologies validations confirm that they were adequate for the purpose proposed. The methodologies developed and validated were applied in Olanzapine determination in several formulation propositions which have been developed and they assisted the pharmacotechnical development team in the definition of the best olanzapine formulation in the 2.5mg strength.
id UFG-2_c5803284dc06797c59b33a497d1be411
oai_identifier_str oai:repositorio.bc.ufg.br:tde/2087
network_acronym_str UFG-2
network_name_str Repositório Institucional da UFG
repository_id_str
spelling LIMA, Eliana Martinshttp://lattes.cnpq.br/7248774319455970http://lattes.cnpq.br/3099392420635562MOURA, Julliana Rodrigues2014-07-29T16:11:45Z2010-10-182009-12-14MOURA, Julliana Rodrigues. Development and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tablets. 2009. 41 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2009.http://repositorio.bc.ufg.br/tede/handle/tde/2087ark:/38995/00130000002dnOlanzapine is an antipsychotic active ingredient and its marketing in Brazil, in the form of terminated product, is protected by patent up to 2011. As it is recent in the pharmaceutical market and there is not a methodology described in officials forms that is capable of assuring the quality of new formulations, the objective of this paper was to characterize Olanzapine physical-chemical parameters, to develop and validate, in accordance with RE N°899, from May 29 th 2003, the analytical methodology for assay and dissolution and to apply the developed and validated methodologies in the pharmacotechnical development of tablets. It was characterized some physicalchemical parameters of solubility and of light absorption (from 200 to 400nm) in several solvents and it was developed and validated assay and dissolution methodologies by spectrophotometry with ultraviolet detection (UV) and the assay by high efficiency liquid chromatography with ultraviolet detection (HPLC-UV) for the quantification of olanzapine present in film coated tablets of 2.5, 5.0 and 10.0mg. The active ingredient presented a low solubility in water and the wave lengths of maximum light absorption were within the range of 254 and 273nm. For the dissolution methodology by UV spectrophotometry, the parameters were chloride acid 0.1 mol/L as the dissolution media, volume of 1,000mL (5 and 10mg of Olanzapine) and 500mL (2.5mg of Olanzapine), apparatus II (paddles) and a rotation of 50 rpm. The spectrophotometric parameters were chloride acid 0.1 mol/L as blank and 259nm of wave length. For the assay methodology by UV spectrophotometry, it was used as a solvent and as a blank solution chloride acid 0.1 mol/L and a wave length of 259nm. It was used a ProStar 210 UV/VIS VARIAN high efficient liquid chromatographer, a C18 (150x4,6)mm 5μm column in room temperature (25ºC), a flux of 0,8mL/min, a wave length of 254nm and a mobile phase constituted of a mixture of monobasic potassium phosphate buffer 0,01 mol/L pH 2,5 and acetonitrile (70:30) for the assay methodology by HPLC-UV. The results found from the parameters of specificity, linearity, accuracy, precision, quantification and detection limits and stability in the methodologies validations confirm that they were adequate for the purpose proposed. The methodologies developed and validated were applied in Olanzapine determination in several formulation propositions which have been developed and they assisted the pharmacotechnical development team in the definition of the best olanzapine formulation in the 2.5mg strength.A olanzapina é um fármaco antipsicótico e sua comercialização no Brasil, na forma de produto acabado, está protegida por patente até 2011. Como é recente no mercado farmacêutico e não há descrição da metodologia em formulários oficiais capazes de assegurar a qualidade das novas formulações, o objetivo deste trabalho foi caracterizar os parâmetros físico-químicos da olanzapina, desenvolver e validar, segundo RE N°899, de 29 de maio de 2003, método analítico para doseamento e dissolução e aplicar os métodos desenvolvidos e validados no desenvolvimento farmacotécnico dos comprimidos. Foram caracterizados alguns parâmetros físico-químicos, de solubilidade e de absorção da luz (200 a 400 nm) em diversos solventes e foram desenvolvidos e validados métodos de doseamento e dissolução por espectrofotometria com detecção ultravioleta (UV) e de doseamento por cromatografia líquida de alta eficiência com detecção ultravioleta (HPLC-UV) para quantificação de olanzapina presente em comprimidos revestidos de 2,5, 5,0 e 10,0 mg. O fármaco apresentou baixa solubilidade em água e os comprimentos de onda de máxima absorção da luz ficaram entre 254 e 273 nm. Para o método de dissolução por espectrofotometria UV, os melhores parâmetros foram ácido clorídrico 0,1 mol/L como meio de dissolução, volume de 1.000 mL (5 e 10 mg de Olanzapina) e 500mL (2,5mg de Olanzapina), aparato II (pás) e rotação de 50rpm. Os parâmetros espectrofotométricos foram ácido clorídrico 0,1 mol/L como branco e 259nm de comprimento de onda. Para o método de doseamento por espectrofotometria UV foi utilizado como solvente e solução branco ácido clorídrico 0,1 mol/L e comprimento de onda de 259 nm. Foi utilizado cromatógrafo líquido de alta eficiência ProStar 210 UV/VIS VARIAN, coluna C18 (150x4,6) mm 5μm a temperatura ambiente (25ºC), fluxo de 0,8mL/min, comprimento de onda de 254 nm e fase móvel constituída por uma mistura de tampão fosfato de potássio monobásico 0,01 mol/L pH 2,5 e acetonitrila (70:30) para o método de doseamento por HPLC-UV. Os resultados encontrados dos parâmetros de especificidade, linearidade, exatidão, precisão, limites de quantificação e detecção e estabilidade nas validações dos métodos confirmam que os mesmos foram adequados para a finalidade proposta. Os métodos desenvolvidos e validados foram aplicados na determinação de olanzapina em várias propostas de formulações que foram desenvolvidas e auxiliou a equipe de desenvolvimento farmacotécnico na definição da melhor formulação da olanzapina na concentração de 2,5mg.Made available in DSpace on 2014-07-29T16:11:45Z (GMT). No. of bitstreams: 1 Dissertacao Julliana Rodrigues Moura.pdf: 204207 bytes, checksum: 56a1561a44aeb00b316511d72cd22e73 (MD5) Previous issue date: 2009-12-14application/pdfhttp://repositorio.bc.ufg.br/TEDE/retrieve/3335/Dissertacao%20Julliana%20Rodrigues%20Moura.pdf.jpgporUniversidade Federal de GoiásMestrado em Ciências FarmacêuticasUFGBRCiências da Saúde - FarmáciaOlanzapinaHPLCDesenvolvimento de MétodoValidaçãoOlanzapineHPLCMethodology DevelopmentValidationCNPQ::CIENCIAS DA SAUDE::FARMACIA::FARMACOTECNIADesenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapinaDevelopment and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tabletsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGORIGINALDissertacao Julliana Rodrigues Moura.pdfapplication/pdf204207http://repositorio.bc.ufg.br/tede/bitstreams/01b01ccb-57e7-4f95-8240-573df7734cd0/download56a1561a44aeb00b316511d72cd22e73MD51THUMBNAILDissertacao Julliana Rodrigues Moura.pdf.jpgDissertacao Julliana Rodrigues Moura.pdf.jpgGenerated Thumbnailimage/jpeg1943http://repositorio.bc.ufg.br/tede/bitstreams/51829d5c-29db-484a-9016-368f898f9cf4/downloadcc73c4c239a4c332d642ba1e7c7a9fb2MD52tde/20872014-07-30 03:04:41.569open.accessoai:repositorio.bc.ufg.br:tde/2087http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttp://repositorio.bc.ufg.br/oai/requesttasesdissertacoes.bc@ufg.bropendoar:2014-07-30T06:04:41Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)false
dc.title.por.fl_str_mv Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
dc.title.alternative.eng.fl_str_mv Development and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tablets
title Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
spellingShingle Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
MOURA, Julliana Rodrigues
Olanzapina
HPLC
Desenvolvimento de Método
Validação
Olanzapine
HPLC
Methodology Development
Validation
CNPQ::CIENCIAS DA SAUDE::FARMACIA::FARMACOTECNIA
title_short Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
title_full Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
title_fullStr Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
title_full_unstemmed Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
title_sort Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
author MOURA, Julliana Rodrigues
author_facet MOURA, Julliana Rodrigues
author_role author
dc.contributor.advisor1.fl_str_mv LIMA, Eliana Martins
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/7248774319455970
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/3099392420635562
dc.contributor.author.fl_str_mv MOURA, Julliana Rodrigues
contributor_str_mv LIMA, Eliana Martins
dc.subject.por.fl_str_mv Olanzapina
HPLC
Desenvolvimento de Método
Validação
topic Olanzapina
HPLC
Desenvolvimento de Método
Validação
Olanzapine
HPLC
Methodology Development
Validation
CNPQ::CIENCIAS DA SAUDE::FARMACIA::FARMACOTECNIA
dc.subject.eng.fl_str_mv Olanzapine
HPLC
Methodology Development
Validation
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS DA SAUDE::FARMACIA::FARMACOTECNIA
description Olanzapine is an antipsychotic active ingredient and its marketing in Brazil, in the form of terminated product, is protected by patent up to 2011. As it is recent in the pharmaceutical market and there is not a methodology described in officials forms that is capable of assuring the quality of new formulations, the objective of this paper was to characterize Olanzapine physical-chemical parameters, to develop and validate, in accordance with RE N°899, from May 29 th 2003, the analytical methodology for assay and dissolution and to apply the developed and validated methodologies in the pharmacotechnical development of tablets. It was characterized some physicalchemical parameters of solubility and of light absorption (from 200 to 400nm) in several solvents and it was developed and validated assay and dissolution methodologies by spectrophotometry with ultraviolet detection (UV) and the assay by high efficiency liquid chromatography with ultraviolet detection (HPLC-UV) for the quantification of olanzapine present in film coated tablets of 2.5, 5.0 and 10.0mg. The active ingredient presented a low solubility in water and the wave lengths of maximum light absorption were within the range of 254 and 273nm. For the dissolution methodology by UV spectrophotometry, the parameters were chloride acid 0.1 mol/L as the dissolution media, volume of 1,000mL (5 and 10mg of Olanzapine) and 500mL (2.5mg of Olanzapine), apparatus II (paddles) and a rotation of 50 rpm. The spectrophotometric parameters were chloride acid 0.1 mol/L as blank and 259nm of wave length. For the assay methodology by UV spectrophotometry, it was used as a solvent and as a blank solution chloride acid 0.1 mol/L and a wave length of 259nm. It was used a ProStar 210 UV/VIS VARIAN high efficient liquid chromatographer, a C18 (150x4,6)mm 5μm column in room temperature (25ºC), a flux of 0,8mL/min, a wave length of 254nm and a mobile phase constituted of a mixture of monobasic potassium phosphate buffer 0,01 mol/L pH 2,5 and acetonitrile (70:30) for the assay methodology by HPLC-UV. The results found from the parameters of specificity, linearity, accuracy, precision, quantification and detection limits and stability in the methodologies validations confirm that they were adequate for the purpose proposed. The methodologies developed and validated were applied in Olanzapine determination in several formulation propositions which have been developed and they assisted the pharmacotechnical development team in the definition of the best olanzapine formulation in the 2.5mg strength.
publishDate 2009
dc.date.issued.fl_str_mv 2009-12-14
dc.date.available.fl_str_mv 2010-10-18
dc.date.accessioned.fl_str_mv 2014-07-29T16:11:45Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv MOURA, Julliana Rodrigues. Development and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tablets. 2009. 41 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2009.
dc.identifier.uri.fl_str_mv http://repositorio.bc.ufg.br/tede/handle/tde/2087
dc.identifier.dark.fl_str_mv ark:/38995/00130000002dn
identifier_str_mv MOURA, Julliana Rodrigues. Development and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tablets. 2009. 41 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2009.
ark:/38995/00130000002dn
url http://repositorio.bc.ufg.br/tede/handle/tde/2087
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Goiás
dc.publisher.program.fl_str_mv Mestrado em Ciências Farmacêuticas
dc.publisher.initials.fl_str_mv UFG
dc.publisher.country.fl_str_mv BR
dc.publisher.department.fl_str_mv Ciências da Saúde - Farmácia
publisher.none.fl_str_mv Universidade Federal de Goiás
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFG
instname:Universidade Federal de Goiás (UFG)
instacron:UFG
instname_str Universidade Federal de Goiás (UFG)
instacron_str UFG
institution UFG
reponame_str Repositório Institucional da UFG
collection Repositório Institucional da UFG
bitstream.url.fl_str_mv http://repositorio.bc.ufg.br/tede/bitstreams/01b01ccb-57e7-4f95-8240-573df7734cd0/download
http://repositorio.bc.ufg.br/tede/bitstreams/51829d5c-29db-484a-9016-368f898f9cf4/download
bitstream.checksum.fl_str_mv 56a1561a44aeb00b316511d72cd22e73
cc73c4c239a4c332d642ba1e7c7a9fb2
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)
repository.mail.fl_str_mv tasesdissertacoes.bc@ufg.br
_version_ 1815172508161146880